Version 2 Last updated 1 November 2021

ab269370 Human CXCL13 SimpleStep ELISA® Kit (BCA-1)

For the quantitative measurement of CXCL13 in human serum, plasma, saliva and cell culture supernatant.

This product is for research use only and is not intended for diagnostic use.

Table of Contents

1. Overview

CXCL13 *in vitro* SimpleStep ELISA® (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of CXCL13 protein in human serum, plasma, saliva and cell culture supernatant.

The SimpleStep ELISA® employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. TMB Development Solution is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow. Signal is generated proportionally to the amount of bound analyte and the intensity is measured at 450 nm. Optionally, instead of the endpoint reading, development of TMB can be recorded kinetically at 600 nm.

CXCL13 (C-X-C motif chemokine 13), also known as BCA-1(B-lymphocyte chemoattractant/B cell-attracting chemokine 1) is a member of the CXC chemokine superfamily. CXCL13 is produced by stromal cells from the liver, spleen, lymph nodes and the gut. It binds to the CXCR5 receptor in lymphoid follicles controlling the homing signal of B cells and subsets of T cells to the lymphoid nodes, compartmentalizing lymphocytes and antigen presenting cells within the follicles of lymphoid tissues. CXCL13 is also required for the embryonic development of most of lymph nodes and Peyer's patches. CXCL13-/- as well as CXCR5-/- mice lack secondary lymphoid structures and show a disrupted splenic architecture.

2. Protocol Summary

Prepare all reagents, samples, and standards as instructed

Add 50 µL standard or sample to appropriate wells

Add 50 µL Antibody Cocktail to all wells

Incubate at room temperature for 1 hour

Aspirate and wash each well three times with 350 µL 1X Wash Buffer PT

Add 100 µL TMB Development Solution to each well and incubate for 10 minutes.

Add 100 µL Stop Solution and read OD at 450 nm

3. Precautions

Please read these instructions carefully prior to beginning the assay.

- All kit components have been formulated and quality control tested to function successfully as a kit.
- We understand that, occasionally, experimental protocols might need to be modified to meet unique experimental circumstances. However, we cannot guarantee the performance of the product outside the conditions detailed in this protocol booklet.
- Reagents should be treated as possible mutagens and should be handle with care and disposed of properly. Please review the Safety Datasheet (SDS) provided with the product for information on the specific components.
- Observe good laboratory practices. Gloves, lab coat, and protective eyewear should always be worn. Never pipet by mouth. Do not eat, drink or smoke in the laboratory areas.
- All biological materials should be treated as potentially hazardous and handled as such. They should be disposed of in accordance with established safety procedures.

4. Storage and Stability

Store kit at +4°C immediately upon receipt. Kit has a storage time of 1 year from receipt, providing components have not been reconstituted.

Refer to list of materials supplied for storage conditions of individual components.

5. Limitations

- Assay kit intended for research use only. Not for use in diagnostic procedures.
- Do not mix or substitute reagents or materials from other kit lots or vendors. Kits are QC tested as a set of components and performance cannot be guaranteed if utilized separately or substituted.

6. Materials Supplied

Item	Quantity	Storage Condition
Human CXCL13 Capture Antibody 10X	600 µL	+4°C
Human CXCL13 Detector Antibody 10X	600 µL	+4°C
Human CXCL13 Lyophilized Recombinant Protein	2 Vials	+4°C
Antibody Diluent 4BI	6 mL	+4°C
Sample Diluent NS	50 mL	+4°C
Wash Buffer PT 10X	20 mL	+4°C
TMB Development Solution	12 mL	+4°C
Stop Solution	12 mL	+4°C
SimpleStep Pre-Coated 96-Well Microplate	96 Wells	+4°C
Plate Seal	1	+4°C

7. Materials Required, Not Supplied

These materials are not included in the kit, but will be required to successfully perform this assay:

- Microplate reader capable of measuring absorbance at 450 or 600 nm.
- Method for determining protein concentration (BCA assay recommended).
- Deionized water.
- Multi- and single-channel pipettes.
- Tubes for standard dilution.
- Plate shaker for all incubation steps.
- Optional: Phenylmethylsulfonyl Fluoride (PMSF) (or other protease inhibitors).

8. Technical Hints

- Samples generating values higher than the highest standard should be further diluted in the appropriate sample dilution buffers.
- Avoid foaming or bubbles when mixing or reconstituting components.
- Avoid cross contamination of samples or reagents by changing tips between sample, standard and reagent additions.
- Ensure plates are properly sealed or covered during incubation steps.
- Complete removal of all solutions and buffers during wash steps is necessary to minimize background.
- As a guide, typical ranges of sample concentration for commonly used sample types are shown below in Sample Preparation (section 11).
- All samples should be mixed thoroughly and gently.
- Avoid multiple freeze/thaw of samples.
- Incubate ELISA plates on a plate shaker during all incubation steps.
- When generating positive control samples, it is advisable to change pipette tips after each step.

- To avoid high background always add samples or standards to the well before the addition of the antibody cocktail.
- This kit is sold based on number of tests. A 'test' simply refers to a single assay well. The number of wells that contain sample, control or standard will vary by product. Review the protocol completely to confirm this kit meets your requirements. Please contact our Technical Support staff with any questions.

9. Reagent Preparation

- Equilibrate all reagents to room temperature (18-25°C) prior to use. The kit contains enough reagents for 96 wells. The sample volumes below are sufficient for 48 wells (6 x 8-well strips); adjust volumes as needed for the number of strips in your experiment.
- Prepare only as much reagent as is needed on the day of the experiment. Capture and Detector Antibodies have only been tested for stability in the provided 10X formulations.

9.1 1X Wash Buffer PT:

Prepare 1X Wash Buffer PT by diluting Wash Buffer PT 10X with deionized water. To make 50 mL 1X Wash Buffer PT combine 5 mL Wash Buffer PT 10X with 45 mL deionized water. Mix thoroughly and gently.

9.2 Antibody Cocktail:

Prepare Antibody Cocktail by diluting the capture and detector antibodies in Antibody Diluent 4BI. To make 3 mL of the Antibody Cocktail combine 300 µL 10X Capture Antibody and 300 µL 10X Detector Antibody with 2.4 mL Antibody Diluent 4BI. Mix thoroughly and gently.

10. Standard Preparation

- Always prepare a fresh set of standards for every use.
- Discard working standard dilutions after use as they do not store well.
- The following section describes the preparation of a standard curve for duplicate measurements (recommended).

10.1 **IMPORTANT:** If the protein standard vial has a volume identified on the label, reconstitute the CXCL13 by adding that volume of Sample Diluent NS indicated on the label. Alternatively, if the vial has a mass identified, reconstitute the CXCL13 standard by adding 500 µL Sample Diluent NS. Hold at room temperature for 10 minutes and mix gently. This is the 6,400 pg/mL **Stock Standard** Solution.

10.1.1 Label eight tubes, Standards 1– 8.

10.1.2 Add 375 µL Sample Diluent NS into tube number 1 and 150 µL of Sample Diluent NS into numbers 2-8.

10.1.3 Use the Stock Standard to prepare the following dilution series. Standard #8 contains no protein and is the Blank control:



11. Sample Preparation

Typical Sample Dynamic Range	
Sample Type	**Range**
Serum	100%
Plasma – Citrate	100%
Plasma – EDTA	100%
Plasma – Heparin	100%
Saliva*	<25%
IFN-r and LPS Treated THP1 Cell Culture Supernatant	0.8 – 25%
PHA-M Treated PBMC Cell Culture Supernatant	3 - 50%
Untreated PBMC Cell Culture Supernatant	50 - 100%

*Based on spiked sample

11.1 Plasma:

Collect plasma using citrate, EDTA or heparin. Centrifuge samples at 2,000 x g for 10 minutes. Assay neat or dilute samples into Sample Diluent NS and assay. Store un-diluted plasma samples at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.

11.2 Serum:

Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 2,000 x g for 10 minutes and collect serum. Assay neat or dilute samples into Sample Diluent NS and assay. Store un-diluted serum at -20°C or below. Avoid repeated freeze-thaw cycles.

11.3 Cell Culture Supernatants:

Centrifuge cell culture media at 2,000 x g for 10 minutes to remove debris. Collect supernatants and assay. Or dilute samples into Sample Diluent NS and assay. Store un-diluted samples at -20°C or below. Avoid repeated freeze-thaw cycles.

11.4 Saliva:

Centrifuge saliva at 800 x g for 10 minutes to remove debris. Collect supernatants. Dilute samples at least 1:4 into Sample Diluent NS and assay. Store un-diluted samples at -20°C or below. Avoid repeated freeze-thaw cycles.

12. Plate Preparation

- The 96 well plate strips included with this kit are supplied ready to use. It is not necessary to rinse the plate prior to adding reagents.
- Unused plate strips should be immediately returned to the foil pouch containing the desiccant pack, resealed and stored at 4°C.
- For each assay performed, a minimum of two wells must be used as the zero control.
- For statistical reasons, we recommend each sample should be assayed with a minimum of two replicates (duplicates).
- Differences in well absorbance or "edge effects" have not been observed with this assay.

13. Assay Procedure

- Equilibrate all materials and prepared reagents to room temperature prior to use.
- We recommend that you assay all standards, controls and samples in duplicate.

13.1 Prepare all reagents, working standards, and samples as directed in the previous sections.

13.2 Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, reseal and return to 4°C storage.

13.3 Add 50 µL of all sample or standard to appropriate wells.

13.4 Add 50 µL of the Antibody Cocktail to each well.

13.5 Seal the plate and incubate for 1 hour at room temperature on a plate shaker set to 400 rpm.

13.6 Wash each well with 3 x 350 µL 1X Wash Buffer PT. Wash by aspirating or decanting from wells then dispensing 350 µL 1X Wash Buffer PT into each well. Wash Buffer PT should remain in wells for at least 10 seconds. Complete removal of liquid at each step is essential for good performance. After the last wash invert the plate and tap gently against clean paper towels to remove excess liquid.

13.7 Add 100 µL of TMB Development Solution to each well and incubate for 10 minutes in the dark on a plate shaker set to 400 rpm.

Given variability in laboratory environmental conditions, optimal incubation time may vary between 5 and 20 minutes. Note: The addition of Stop Solution will change the color from blue to yellow and enhance the signal intensity about 3X. To avoid signal saturation, proceed to the next step before the high concentration of the standard reaches a blue color of O.D.600 equal to 1.0.

13.8 Add 100 µL of Stop Solution to each well. Shake plate on a plate shaker for 1 minute to mix. Record the OD at 450 nm. This is an endpoint reading.

13.9 Alternative to 13.7 – 13.8: Instead of the endpoint reading at 450 nm, record the development of TMB Substrate kinetically. Immediately after addition of TMB Development Solution begin recording the blue color development with elapsed

time in the microplate reader prepared with the following settings:

Mode	Kinetic
Wavelength:	600 nm
Time:	up to 20 min
Interval:	20 sec - 1 min
Shaking:	Shake between readings

Δ **Note**: that an endpoint reading can also be recorded at the completion of the kinetic read by adding 100 µL Stop Solution to each well and recording the OD at 450 nm.

13.10 Analyze the data as described below.

14. Calculations

14.1 Calculate the average absorbance value for the blank control (zero) standards. Subtract the average blank control standard absorbance value from all other absorbance values.

14.2 **Create a standard curve** by plotting the average blank control subtracted absorbance value for each standard concentration (y-axis) against the target protein concentration (x-axis) of the standard. Use graphing software to draw the best smooth curve through these points to construct the standard curve.

Δ **Note:** Most microplate reader software or graphing software will plot these values and fit a curve to the data. A four-parameter curve fit (4PL) is often the best choice; however, other algorithms (e.g. linear, semi-log, log/log, 4-parameter logistic) can also be tested to determine if it provides a better curve fit to the standard values.

14.3 Determine the concentration of the target protein in the sample by interpolating the blank control subtracted **absorbance values against the standard curve**. Multiply the resulting value by the appropriate sample dilution factor, if used, to obtain the concentration of target protein in the sample.

14.4 Samples generating absorbance values greater than that of the highest standard should be further diluted and reanalyzed. Similarly, samples which measure at an absorbance values less than that of the lowest standard should be retested in a less dilute form.

15. Typical Data

Typical standard curve – data provided **for demonstration purposes only**. A new standard curve must be generated for each assay performed.



Standard Curve Measurements			
Concentration (pg/mL)	O.D 450 nm		Mean O.D
	1	2	
0	0.062	0.066	0.064
6.25	0.134	0.135	0.135
12.5	0.204	0.214	0.209
25	0.318	0.340	0.329
50	0.583	0.587	0.585
100	1.103	1.156	1.129
200	2.034	1.986	2.010
400	3.339	3.396	3.367

Figure 1. Example of human CXCL13 standard curve in Sample Diluent NS. The CXCL13 standard curve was prepared as described in Section 10. Raw data values are shown in the table. Background-subtracted data values (mean +/- SD) are graphed.

16. Typical Sample Values

SENSITIVITY –

The calculated minimal detectable dose (MDD) is 1 pg/mL. The MDD was determined by calculating the mean of zero standard replicates (n=12) and adding 2 standard deviations then extrapolating the corresponding concentration.

RECOVERY –

Three concentrations of CXCL13 recombinant protein were spiked in duplicate to the indicated biological matrix to evaluate signal recovery in the working range of the assay.

Sample Type	Average % Recovery	Range (%)
100% Serum	90	88 - 94
100% Plasma - Citrate	82	79 - 85
100% Plasma - EDTA	91	88 - 94
100% Plasma - Heparin	80	75 - 85
25% Saliva	87	78 - 97
8% THP1 IFN-r and LPS Treated Cell Culture Supernatant	117	111 - 123
100% THP1 Untreated Cell Culture Supernatant	90	85 - 93
25% PBMC PHA-M Treated Cell Culture Supernatant	113	109 - 118
100% PBMC Untreated Cell Culture Supernatant	114	107 - 127
100% Cell Culture Media*	84	78 - 88

*Media is RPMI 1640 containing 10% fetal bovine serum.

Linearity of Dilution

Linearity of dilution is determined based on interpolated values from the standard curve. Linearity of dilution defines a sample concentration interval in which interpolated target concentrations are directly proportional to sample dilution.

Native CXCL13 was measured in the following biological samples in a 2-fold dilution series. Sample dilutions are made in Sample Diluent NS.

Dilution Factor	Interpolated value	25% THP1 IFN-r and LPS Treated Cell Culture Supernatant	50% PBMC PHA-M Treated Cell Culture Supernatant
Undiluted	pg/mL	322	160
	% Expected value	**100**	**100**
2	pg/mL	159	84
	% Expected value	**99**	**105**
4	pg/mL	80.1	42.2
	% Expected value	**99**	**106**
8	pg/mL	39.0	22.2
	% Expected value	**97**	**111**
16	pg/mL	21.4	10.5
	% Expected value	**106**	**105**

Neat pooled saliva sample from healthy donors was measured in duplicate. The value was below the detectable range of the assay.

Recombinant CXCL13 was spiked into the following biological samples and diluted in a 2-fold dilution series in Sample Diluent NS.

Dilution Factor	Interpolated value	100% Human Serum	100% Human Plasma (Citrate)	100% Human Plasma (EDTA)	100% Human Plasma (Heparin)	25% Human Saliva
Undiluted	pg/mL	232	221	296	249	59
	% Expected value	**100**	**100**	**100**	**100**	**100**
2	pg/mL	106	112	151	130	31
	% Expected value	**91**	**101**	**102**	**104**	**106**
4	pg/mL	55.5	58.2	74.7	69.2	17.0
	% Expected value	**96**	**105**	**101**	**111**	**115**
8	pg/mL	28.1	29.1	36.1	36.4	9.0
	% Expected value	**97**	**105**	**98**	**117**	**121**
16	pg/mL	14.5	15.8	17.9	18.0	ND
	% Expected value	**100**	**114**	**97**	**116**	**ND**

ND-Not Determined, interpolated value below the 7th standard.

PRECISION –

Mean coefficient of variations of interpolated values of CXCL13 from two concentrations of spiked cell culture media within the working range of the assay.

	Intra-Assay	Inter-Assay
n =	8	3
CV (%)	2.5	0.9



Figure 2. Interpolated concentrations of native CXCL13 in human THP-1 cell culture supernatant treated or untreated with Hu-IFN-r (1 µg/ml, 8 hours) then LPS (1 µg/ml, 17 hours) and PBMC cell culture supernatant treated with or without 1.5% PHA-M for 36 hours. The concentrations of CXCL13 were measured in duplicates, interpolated from the CXCL13 standard curves and corrected for sample dilution. Undiluted samples are as follows: THP-1 treated 25%, THP-1 untreated 100%, PBMC treated 50% and PBMC untreated 100%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean CXCL13 concentration was determined to be 1,292 pg/mL in neat THP-1 treated supernatant, undetectable in untreated THP-1 supernatant, 337 pg/mL in treated neat PBMC supernatant and 25 pg/mL in untreated neat PBMC supernatant.



Figure 3. Interpolated concentrations of native CXCL13 in human serum, plasma-citrate, plasma-EDTA and plasma-heparin samples. The concentrations of CXCL13 were measured in duplicates in neat samples and interpolated from the CXCL13 standard curves. The interpolated values are plotted (mean +/- SD, n=2). The mean CXCL13 concentration was determined to be 13 pg/mL in serum, 12.6 pg/mL in plasma-citrate, 13.1 pg/mL in plasma-EDTA and 10 pg/mL in plasma-heparin.



Figure 4. Serum from ten individual healthy human female donors was measured in duplicate. Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean of detectable CXCL13 concentration was determined to be 12.7 pg/mL with a range of undetectable to 18.3 pg/mL.

17. Assay Specificity

This kit recognizes both native and recombinant human CXCL13 protein in serum, plasma (citrate, EDTA and heparin), saliva and cell culture supernatant samples only.

Urine, milk, cell and tissue extract samples have not been tested with this kit.

18. Species Reactivity

This kit recognizes human CXCL13 protein.

Monkey reactivity was determined by measuring neat Rhesus macaque serum sample, interpolating the protein concentrations from the human standard curve, and expressing the interpolated concentrations as a percentage of the protein concentration in human serum assayed at the same dilution.

Species	% Reactive
Rhesus macaque	63

Other species reactivity not determined.

Please contact our Technical Support team for more information.

19. Troubleshooting

Problem	Reason	Solution
Poor standard curve	Inaccurate Pipetting	Check pipettes
	Improper standard dilution	Prior to opening, briefly spin the stock standard tube and dissolve the powder thoroughly by gentle mixing
Low Signal	Incubation times too brief	Ensure sufficient incubation times; increase to 2 or 3 hour standard/sample incubation
	Inadequate reagent volumes or improper dilution	Check pipettes and ensure correct preparation
	Incubation times with TMB too brief	Ensure sufficient incubation time until blue color develops prior addition of Stop solution
Large CV	Plate is insufficiently washed	Review manual for proper wash technique. If using a plate washer, check all ports for obstructions.
	Contaminated wash buffer	Prepare fresh wash buffer
Low sensitivity	Improper storage of the ELISA kit	Store your reconstituted standards at -80°C, all other assay components 4°C. Keep TMB Development Solution protected from light.
Precipitate in Diluent	Precipitation and/or coagulation of components within the Diluent.	Precipitate can be removed by gently warming the Diluent to 37°C.

20. Notes

Technical Support

For all technical or commercial enquiries please go to:

www.abcam.com/contactus
www.abcam.cn/contactus (China)
www.abcam.co.jp/contactus (Japan)